Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Endocrine 1CNS 1

Conditions

von Hippel-Lindau Disease 1Pheochromocytoma 1Paraganglioma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Adenoma, Islet Cell 1

Interventions

Carboplatin 6Specimen Handling 5Rituximab 5amivantamab 4Prednisone 4olaparib 3lazertinib 3acalabrutinib 3X-Rays 3Pemetrexed 3Nivolumab 3Magnetic Resonance Spectroscopy 3Dexamethasone 3Cyclophosphamide 3Ado-Trastuzumab Emtansine 3Abiraterone Acetate 3trastuzumab deruxtecan 2talquetamab 2pertuzumab 2pembrolizumab 2osimertinib 2niraparib 2ipatasertib 2erdafitinib 2entrectinib 2durvalumab 2daratumumab 2belzutifan 2atezolizumab 2apalutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × belzutifan × 30 days × Clear all
NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
755 enrolled 28 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡